Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Lattanzi

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Vaccine|April 24, 2012
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodiesElisa Faenzi, Luisanna Zedda, Monia Bardelli, et al.
The Lancet. Respiratory Medicine|January 13, 2022
Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trialStefan Andreas, Marco Testa, Laurent Boyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 9, 2026
Safety, Efficacy, and Immunogenicity of a Multivalent Adjuvanted S. aureus Vaccine in Adults with Recent Skin And Soft Tissue Infections: An Observer-blind, Randomized, Placebo-controlled, Multinational Phase 1/2 TrialEugene Athan, Richard N Greenberg, David A Baker, et al.
Human Vaccines & Immunotherapeutics|November 28, 2017
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adultsGeert Leroux-Roels, Maria Lattanzi, Claudia Dovali Solis, et al.
Open Forum Infectious Diseases|November 25, 2024
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young AdultsTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. Infectious Diseases|December 8, 2024
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trialTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
Vaccine|October 12, 2021
A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind studyCorinne Vandermeulen, Isabel Leroux-Roels, James Vandeleur, et al.
Human Vaccines & Immunotherapeutics|October 6, 2021
Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adultsJavier Díez-Domingo, Juan Carlos Tinoco, Airi Poder, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Vaccine|April 24, 2012
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodiesElisa Faenzi, Luisanna Zedda, Monia Bardelli, et al.
The Lancet. Respiratory Medicine|January 13, 2022
Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trialStefan Andreas, Marco Testa, Laurent Boyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 9, 2026
Safety, Efficacy, and Immunogenicity of a Multivalent Adjuvanted S. aureus Vaccine in Adults with Recent Skin And Soft Tissue Infections: An Observer-blind, Randomized, Placebo-controlled, Multinational Phase 1/2 TrialEugene Athan, Richard N Greenberg, David A Baker, et al.
Human Vaccines & Immunotherapeutics|November 28, 2017
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adultsGeert Leroux-Roels, Maria Lattanzi, Claudia Dovali Solis, et al.
Open Forum Infectious Diseases|November 25, 2024
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young AdultsTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. Infectious Diseases|December 8, 2024
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trialTerry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
Vaccine|October 12, 2021
A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind studyCorinne Vandermeulen, Isabel Leroux-Roels, James Vandeleur, et al.
Human Vaccines & Immunotherapeutics|October 6, 2021
Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adultsJavier Díez-Domingo, Juan Carlos Tinoco, Airi Poder, et al.
Pageof 5